{"id":"hx575-epoetin-alfa-hexal-ag","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Thrombotic events (venous thromboembolism, stroke)"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Pure red cell aplasia (rare)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Epoetin alfa is a recombinant human erythropoietin that mimics the natural hormone responsible for red blood cell production. By activating erythropoietin receptors on erythroid progenitor cells in the bone marrow, it promotes proliferation and differentiation, increasing hemoglobin and hematocrit levels. HX575 is a biosimilar formulation developed by Hexal AG (Sandoz) intended to be therapeutically equivalent to reference epoetin alfa products.","oneSentence":"HX575 is a biosimilar epoetin alfa that stimulates erythropoiesis by binding to and activating the erythropoietin receptor on bone marrow progenitor cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:47:38.123Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Anemia of chronic kidney disease"},{"name":"Chemotherapy-induced anemia"},{"name":"Anemia in patients with HIV infection"}]},"trialDetails":[{"nctId":"NCT00666835","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of HX575 Hexal AG vs ERYPO® for the Treatment of Anemia in Hemodialysis Patients","status":"COMPLETED","sponsor":"Sandoz","startDate":"2004-04","conditions":"Anemia","enrollment":478},{"nctId":"NCT00711958","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of HX575 in the Treatment of Chemotherapy Associated Anemia in Cancer Patients","status":"COMPLETED","sponsor":"Sandoz","startDate":"2004-11","conditions":"Anemia","enrollment":114}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Binocrit, Abseamed"],"phase":"phase_3","status":"active","brandName":"HX575 epoetin alfa Hexal AG","genericName":"HX575 epoetin alfa Hexal AG","companyName":"Sandoz","companyId":"sandoz","modality":"Small molecule","firstApprovalDate":"","aiSummary":"HX575 is a biosimilar epoetin alfa that stimulates erythropoiesis by binding to and activating the erythropoietin receptor on bone marrow progenitor cells. Used for Anemia of chronic kidney disease, Chemotherapy-induced anemia, Anemia in patients with HIV infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}